Biden administration urged to license prostate cancer drug patents in a bid to lower its cost; Virginia governor vetoes plans to create a prescription drug affordability board

Taking stock of the drug industry, from the lab to the medicine chest

April 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Biden administration urged to license prostate cancer drug patents in a bid to lower its cost The groups say the government has the right under federal laws to authorize "qualified companies" to make and sell generic versions of Xtandi. By Ed Silverman STAT+ | Virginia governor vetoes plans to create a prescription drug affordability board A board would have set upper payment limits used to cap the cost of a select number of medicines for Virginia residents. By Ed Silverman STAT+ | Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells The new biotech was launched by the team behind Karuna Therapeutics, which was recently picked up in a multibillion-dollar deal. By Andrew Joseph Adobe STAT+ | Biotech startups post strongest financing numbers in two years Venture-backed biopharma companies raised $6.8 billion in the first three months of the year, according to early data compiled by HSBC. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser